Background Patients who have had inadequate response to tumour necrosis factor inhibitors
have fewer treatment options and are generally more treatment refractory to subsequent …

Background Previous bisphosphonate treatment attenuates the bone-forming effect of
teriparatide. We compared the effects of 12 months of romosozumab (AMG 785), a sclerostin …

Objective To assess the safety and efficacy of secukinumab, a fully human monoclonal anti-interleukin-17A
antibody, in patients with rheumatoid arthritis (RA). Methods Patients (n=237) …

Objective To evaluate the efficacy and safety of ustekinumab in 3 randomized, placebo‐controlled
studies in patients with axial spondyloarthritis (SpA). Studies 1 and 2 included patients …

Background Upadacitinib is a Janus kinase inhibitor under evaluation for the treatment of
psoriatic arthritis (PsA). We evaluated upadacitinib in patients with PsA and prior inadequate …

Background Ixekizumab, a high-affinity interleukin-17A (IL-17A) monoclonal antibody, has
previously shown efficacy in radiographic axial spondyloarthritis (also known as ankylosing …

Background Secukinumab, an anti–interleukin-17A monoclonal antibody, improved the
signs and symptoms of ankylosing spondylitis (AS) in two phase 3 studies (MEASURE 1 and …

Objectives To compare the efficacy, safety, immunogenicity and pharmacokinetics (PK) of
SB2 to the infliximab reference product (INF) in patients with moderate to severe rheumatoid …

Objective To evaluate the efficacy and safety of secukinumab in patients with active rheumatoid
arthritis (RA) who had an inadequate response to or intolerance of tumor necrosis factor (…

Background Odanacatib, a cathepsin K inhibitor, reduces bone resorption while maintaining
bone formation. Previous work has shown that odanacatib increases bone mineral density …